Navigation Links
Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
Date:9/8/2011

SAN MATEO, Calif., Sept. 8, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a company focused on the development of novel therapeutics for cardiovascular disease, today announced that Daron Evans, Chief Financial Officer, will present at the Rodman & Renshaw 13th Annual Global Investment Conference on Tuesday, September 13, 2010 at 2:50 p.m. (Eastern Time) at The Waldorf Astoria in New York City, New York..

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally-designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)... , April 18, 2017 Research ... of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, ... ... in molecular imaging equipment revenues as well as growth in ... This will provide value to market participants that design and ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is a ... SUPERFOODS! , RawTrition is taking nutrients to the next level! The ... recognizes its raw form (unlike the synthetically made options that are on the market). ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
(Date:4/25/2017)... Amherst, NY (PRWEB) , ... April 25, 2017 , ... ... much stress at work can also decrease overall productivity and performance in the workplace. ... their employees. , During the last few weeks of April, Clearview Resolution Services will ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are ... dental fear and require sedation to receive dental care. The doctors offer three treatment ... from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre ...
Breaking Medicine News(10 mins):